Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 22, 2018 in Colorectal cancer | 0 comments

In a nutshell

This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients.

Some background

The standard treatment for mCRC is chemotherapy combined with targeted therapy. Targeted therapy attacks specific proteins of cancer cells which stops their growth. This therapy is often used in combination with chemotherapy to improve treatment efficacy. Regorafenib is a targeted therapy.

A prior study showed that patients treated with regorafenib had a 23% improvement in the odds of a better survival. The most common negative side effects were skin reactions, tiredness, diarrhea, and hypertension. However, these studies were done on a small group of patients.Therefore, the safety of this treatment still needs to be assessed in a larger patient population.

Methods & findings

This study included 2864 patients with mCRC from 25 countries who did not respond to previous standard treatments. All patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Side effects and progression-free survival (PFS; time from treatment to progression) were assessed. Patients were followed up for an average of 3.5 months.

The treatment dose was reduced in 46% of these patients and 9% stopped treatment due to side effects.  Less than 1% of the patients had severe side effects. The most common mild side effects were high blood pressure (15%), skin reaction in the hands and in the feet (14%), tiredness (13%), diarrhea (5%) and low levels of phosphate (5%; which may cause weakness and impaired breathing).

Average PFS was 2.7 months. 23% of regorafenib-treated patients had a PFS longer than 4 months. 

The bottom line

This study showed that regorafenib is an effective option to treat patients with mCRC, with manageable side effects.

The fine print

This study was funded by Bayer, the producer of regorafenib

Published By :

The Oncologist

Date :

Sep 06, 2018

Original Title :

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

click here to get personalized updates